06-19-2018 – ETBI – EastGate Biotech Strikes Investment and Licensing Collaboration with Nico Innovapharma for Liquid Insulin Mouth Rinse Solution for the European Market
Investment and Product License Includes Licensing Fee and Development Costs WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / June 19, 2018 /Ā EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, announced it entered into a binding Memorandum of Understanding (MOU) with Nico Innovapharma (www.nicoinnovagroup.com) (www.nilamedica.com), an innovative start up under incorporation, with its principal headquarters in Brescia, Italy. The scope of the MOU is for the licensing of the company's liquid insulin mouth rinse solution. The terms of the MOU detail...